Entologi Completes Acquisition of Hatch Science

FOLLOWING the major shareholding made by RTS Life Science last year, new owner, Entologi, has completed the acquisition of Hatch Science, a US-based pharmaceutical testing business for $1 million (£600,000).

Carl Krajewski, CEO of Entologi explains: “RTS originally felt Hatch’s products and technology would align nicely with its existing inhaler and tablet testing products by adding dissolution and content uniformity testing functionality.  This premise is coming to fruition as both RTS and Hatch technical teams are collaborating on new products centred on quality control in the life science and biotech sectors.  This acquisition also provides us with a valuable US base from which to bring the wider Entologi Group offering to North America and to service our additional customers.”

Entologi, the UK’s fastest growing engineering group, has rebranded Hatch as a subsidiary of the RTS Group and it will be headed by RTS Managing Director, Gary Walsh.  “In addition to enabling the life science business to better serve its US clients’ from our East Coast base, it will also help fuel the growth of other companies within the Entologi Group, such as HMK drives and controls  and our, clean room specialists, Specific Environments”, comments Walsh.